Using Nanopore Sequencing to Identify Pathogens in Eye Infections
Nanopore Sequencing in Ophthalmology - a Paradigm Shift in Pathogen Determination?
This study is testing whether a new device can quickly identify germs causing eye infections in patients undergoing surgery, to see if it works better than the usual methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Medical University of Graz Academic / other |
| Locations | 1 site (Graz, Styria) |
| Trial ID | NCT05372861 on ClinicalTrials.gov |
What this trial studies
This pilot study assesses the feasibility of using the Oxford Nanopore MinION device to identify pathogens in vitrectomy samples from patients with endophthalmitis. During routine vitrectomy, vitreous samples and anterior chamber taps are collected and split for both standard microbial culture and nanopore sequencing. The results from nanopore sequencing are then compared to traditional culture methods to evaluate their effectiveness in pathogen identification. Clinical data regarding visual function and other features are also collected to provide a comprehensive overview of patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with endophthalmitis who are undergoing vitrectomy.
Not a fit: Patients who are unable to provide informed consent or are participating in other studies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to faster and more accurate identification of pathogens in endophthalmitis, improving treatment outcomes for patients.
How similar studies have performed: While the use of nanopore sequencing in infectious diseases is promising, this specific application in ophthalmology is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Eyes of patients with endophthalmitis Exclusion Criteria: * No informed consent possible * Participation in other studies
Where this trial is running
Graz, Styria
- Universitäts Augenklinik Graz — Graz, Styria, Austria (Recruiting)
Study contacts
- Study coordinator: Michael Sommer, MD
- Email: michael.sommer@medunigraz.at
- Phone: 004331638531033
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.